drugset / Trial / NCT06085521
A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis
RandomizedParallel-groupDouble-blindTreatment
Summary
Participants who meet eligibility criteria will be randomized in a 1:1:1 ratio to receive a twice daily oral LNK01001 dose A or LNK01001 dose B or matching placebo for 12 weeks.
Timeline
- Start
- 2022-01-26
- Primary completion
- 2023-06-14
- Completion
- 2023-06-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zemprocitinib | Small molecule | — | Oral |